Customizable, incision-free therapies

    Profound Medical develops and markets customizable, incision-free therapies which combine real-time Magnetic Resonance (“MR”) imaging, thermal ultrasound and closed-loop thermal feedback control for radiation-free ablation of tissue.

    Men’s Health

    Its TULSA-PRO® system is a novel technology that combines real-time MRI, robotically-driven transurethral thermal ultrasound and closed-loop temperature feedback control. The system is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help men’s natural functional abilities.

    Localized Prostate Cancer 

    Approximately 200,000 men are diagnosed with prostate cancer each year in North America (US + Canada). Using the Gleason Grade (GG) Score patients are staged in category 1 for low risk patients and 2 or higher for intermediate or high risk.

    Today, the standard of care for treatment of GG2 and higher is either radical prostatectomy or radiation. Clinical evidence shows that these procedures are associated with serious side effects including urinary and/or rectal incontinence and erectile dysfunction creating an opportunity for new function preserving procedures that do not preclude additional intervention if needed in the future.

    TULSA-PRO combines real-time MRI, robotically-driven transurethral ultrasound and closed loop temperature feedback control, to provide customizable and predictable ablation of a surgeon-defined prostate volume. For patients with organ confined disease, clinical data shows that the TULSA procedure has a favorable safety profile and low impact on patient quality of life while maintaining or further improving clinical effectiveness.

    Read more on TULSA-PRO

    CAUTION: TULSA-PRO® is approved for commercial sale in the USA (K191200) & EU (CE 2797). Rx only device.

    For all other Regulatory jurisdictions, please contact us at info@profoundmedical.com for more information regarding the regulatory status of the device.

    Women’s Health

    Extend your options in women’s health and oncology. Sonalleve opens up incision-free alternatives to traditional surgical treatments of uterine fibroids and enables incision-free, non-ionizing radiation palliative pain treatment of bone metastases.

    Sonalleve MR-HIFU is designed for incision-free procedures. High Intensity Focused Ultrasound (HIFU) heats and coagulates tissue deep inside the body through the intact skin. MRI measures temperature changes within the human body, making it useful for planning and monitoring thermal ablation processes such as HIFU.

    Sonalleve is an exciting therapy platform that extends your options for women with painful fibroids or adenomyosis. It enables you to perform patient friendly, incision-free ablation of these benign growths in the uterus.

    A Fast, Low-Pain Alternative To Surgery

    With Sonalleve, you can offer women with symptomatic uterine fibroids or adenomyotic tissue a therapy option that does not exclude future pregnancy.* Patients usually go home the same day and return to their routines within two days.

    Women who are planning on becoming pregnant should consult their physician before seeking MR-HIFU treatment.

    Read more on SONALLEVE

    Pain Palliation

    The Sonalleve platform extends your options for alleviating the suffering of cancer patients. It enables you to perform incision-free, non-ionizing radiation palliative pain treatment of bone metastases.

    Sonalleve is designed to quickly relieve pain associated with bone metastasis. It targets and thermally ablates specific periosteal nerves while the patient is under analgesia.

    Read more on SONALLEVE

    Learn More

    Contact Profound Medical to set up a meeting to learn more about how our technologies can work for you.

    CAUTION: Products shown may not be approved for sale in all jurisdictions. Rx only device.
    Contact us at info@profoundmedical.com for more information regarding the regulatory status of the device.

    107392A